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Abstract
Background: Schistosomiasis is the most important human helminth infection due to its impact on public health. The
clinical manifestations are chronic and significantly decrease an individual’s quality of life. Infected individuals suffer
from long-term organ pathologies including fibrosis which eventually leads to organ failure. The development of a
vaccine against this parasitic disease would contribute to a long-lasting decrease in disease spectrum and transmission.
Method: Our group has chosen Schistosoma mansoni (Sm) cathepsin B, a peptidase involved in parasite feeding, as a
prospective vaccine candidate. Our experimental formulation consisted of recombinant Sm-cathepsin B formulated
in Montanide ISA 720 VG, a squalene based adjuvant containing a mannide mono-oleate emulsifier. Parasitological
burden was assessed by determining adult worm, hepatic egg, and intestinal egg numbers in each mouse. Serum was
used in ELISAs to evaluate production of antigen-specific antibodies, and isolated splenocytes were stimulated with the
antigen for the analysis of cytokine secretion levels.
Results: The Sm-cathepsin B and Montanide formulation conferred protection against a challenge infection by
significantly reducing all forms of parasitological burdens. Worm burden, hepatic egg burden and intestinal egg
burden were decreased by 60 %, 62 %, and 56 %, respectively in immunized animals compared to controls (P = 0.0002,
P < 0.0001, P = 0.0009, respectively). Immunizations with the vaccine elicited robust production of Sm-cathepsin B
specific antibodies (endpoint titers = 122,880). Both antigen-specific IgG1 and IgG2c titers were observed, with the
former having more elevated titers. Furthermore, splenocytes isolated from the immunized animals, compared to
control animals, secreted higher levels of key Th1 cytokines, IFN-γ, IL-12, and TNF-α, as well as the Th2 cytokines
IL-5 and IL-4 when stimulated with recombinant Sm-cathepsin B. The Th17 cytokine IL-17, the chemokine CCL5, and
the growth factor GM-CSF were also significantly increased in the immunized animals compared to the controls.
Conclusion: The formulation tested in this study was able to significantly reduce all forms of parasite burden, stimulate
robust production of antigen-specific antibodies, and induce a mixed Th1/Th2 response. These results highlight the
potential of Sm-cathepsin B/Montanide ISA 720 VG as a vaccine candidate against schistosomiasis.
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Background
Schistosomiasis, caused by trematodes belonging to the
Schistosoma genus, is an important neglected tropical
disease with a substantial impact on public health. Over
200 million people are infected with approximately half
of these being school aged children [1–3]. It has long
been argued that the schistosomiasis disease burden is
greatly underestimated, and it has been suggested that
the number of infected individuals surpasses 400 million
[4]. This underestimation is likely due to the inability of
current diagnostic methods to detect light infections.
Schistosomiasis is a chronic illness that significantly
diminishes quality of life, and, in affected children, inter-
feres with growth and cognitive development [2, 5, 6].
Treatment of schistosomiasis relies solely on the drug
praziquantel which is distributed in mass drug administra-
tion control programs. However, program outcomes have
been disappointing [3]. In 2011, of the 112 million
children in need of praziquantel, only 16 million received
treatment [7]. School-based mass drug administration
programs do not take into account that as many as 40 %
of children in sub-Saharan Africa are not enrolled in
school [8]. It has been shown that less than 5 % of the
schistosomiasis affected population is treated with prazi-
quantel, indicating that control programs are not reaching
sufficient coverage [9]. Furthermore, these mass drug
administration programs are not sustainable because
praziquantel does not prevent re-infection. Therefore con-
tinuous drug distribution at an optimal timing is necessary
in order to maintain disease control and break the trans-
mission cycle [8–10]. The current amount of praziquantel
donated by the various sources, such as the Schistosomia-
sis Control Initiative, MedPharm, and Merck KgaA, is not
sufficient to meet the global need [9]. Vaccines, and/or
chemotherapy combined with vaccination, present the
best strategy for long-term sustained control of schisto-
somiasis. An anti-schistosome vaccine could contribute to
decreased disease spectrum and transmission by reducing
worm and egg burdens. It has been stated that even a
partially effective anti-schistosome vaccine could signifi-
cantly help accelerate the elimination of schistosomiasis if
incorporated with other control efforts such as mass drug
administration, intermediate host control, and improved
sanitation [11, 12].
Our group has chosen to focus on Schistosoma man-
soni (Sm) cathepsin B as a vaccine candidate. This cyst-
eine peptidase, originally cloned and identified by
Klinkert et al., [13, 14] is predominantly found in the
adult worm and migratory larva. Sm-cathepsin B is in-
volved in the digestion of blood macromolecules. It plays
a key role in hemoglobin degradation and is involved in
digestion of host serum albumin or immunoglobulin G
[15–19]. The physiological importance of Sm-cathepsin
B has been highlighted by RNA interference (RNAi)
technology which demonstrated that suppression of
cathepsin B results in impeded parasite growth [20]. The
present study was designed to investigate the protective
potential of a Sm-cathepsin B formulation with the adju-
vant Montanide ISA 720 VG (SEPPIC Inc., Fairfield, NJ,
USA) in a mouse model of schistosomiasis. Montanide
is a squalene based adjuvant containing a mannide
mono-oleate emulsifier. The adjuvant forms water-in-oil
droplets that allow for slow antigen release at the injec-
tion site. Montanide was chosen as an adjuvant because
it is acceptable for use in humans; it is both safe and
well-tolerated. The different Montanide adjuvants have
been used in over fifty clinical trials including malaria,
cancer, and human immunodeficiency virus (HIV)
vaccine trials [21–23]. These adjuvants have also
continuously shown to elicit robust antibody responses.
In this communication, we report that an immunization
regimen involving a formulation of recombinant Sm-
cathepsin B and Montanide ISA 720 VG can signifi-
cantly reduce worm and egg burdens.
Methods
Ethics statement
All animal procedures were conducted in accordance
with Institutional Animal Care and Use Guidelines and
were approved by the Animal Care and Use Committee
at McGill University (Animal Use Protocol 7625).
Cloning, expression, and purification of Sm-cathepsin B
The recombinant Schistosoma mansoni cathepsin B
protein was generated as described elsewhere [24]. Briefly,
Schistosoma mansoni cathepsin B (Genbank accession
number M21309.1) cDNA was synthesized by GenScript
in pUC57 with modifications in order to be suitable for
expression in the yeast Pichia pastoris [25]. The modifica-
tion process used the following primers: primer a, 5′-CA
ACTTGTGTGTGATTCTTTCGAAC-3′ and primer b,
5′-GTTCGAAAGAATCACACACAGGTTG-3′ [25]. Sm-
cathepsin B cDNA was inserted in the pPinkα-HC vector
and then transformed into yeast cells belonging to the
PichiaPink™ strain 1. The recombinant Sm-cathepsin B
expression was carried out following the manufacturer’s
recommendations for the PichiaPink expression system
(Invitrogen, Burlington, ON). Briefly, yeast cells were
cultured in a flask containing buffered complex glycerol
medium (1 % yeast extract [Fisher Scientific, Ottawa,
ON], 2 % peptone [BD Biosciences, Mississauga, ON],
100 mM potassium phosphate pH 6.0 [Bioshop Canada
Inc., Burlington, ON], 1.34 % yeast nitrogen base without
amino acids with ammonium sulphate [Bioshop Canada
Inc.], 0.00004 % biotin [Supelco, Bellefonte, PA], 1 %
glycerol [Bioshop Canada Inc.]) at 28 °C with shaking
(250 rpm) until it reached log phase growth (OD600 = 6).
The cells were harvested by centrifugation at 3,000 × g for
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five minutes at room temperature. The pellet was resus-
pended in 200 ml induction media: buffered complex
methanol medium (same recipe as BMGY except 1 %
methanol [Fisher Scientific, Ottawa, ON] was used instead
of glycerol). The culture was grown for three days at 28 °C
with shaking (250 rpm). Every 24 h, methanol was added
to a final concentration of 0.5 %. After the three days, the
cells were harvested by centrifugation at 3,000 × g for five
minutes at room temperature. The resulting expressed
recombinant protein was purified using Ni-NTA affinity
chromatography (Ni-NTA Superflow by QIAGEN, Venlo,
Limburg, Netherlands). Expression quality of recombinant
Sm-cathepsin B was analyzed by Coomassie staining of
polyacrylamide gel and western blot using antibodies
directed against the His-tag (Sigma-Aldrich, St. Louis,
Mo) followed by a HRP-conjugated secondary anti-
body (anti-mouse IgG-HRP from Jackson Immunore-
search Laboratories, West Grove, PA).
Immunization protocol
Female 6–8 week old C57BL/6 mice were purchased
from Charles River Laboratories (Senneville, Qc). There
were three immunization groups containing 10 mice
each. The immunization groups were as follows: saline
control mice were injected with 50 μl of phosphate
buffered saline (PBS) (Wisent Bio Products, Saint-Jean-
Baptiste). Adjuvant control mice received 50 μl of a
70 % volume formulation of Montanide ISA 720 VG
(SEPPIC Inc., Fairfield, NJ). The experimental mice were
immunized with a 50 μl solution of 20 μg recombinant Sm-
cathepsin B in a 70 % volume formulation of Montanide
ISA 720 VG. Each mouse was immunized intramuscularly
at weeks 0, 3 and 6. The immunization timeline and the
vaccine formulation (antigen: adjuvant ratio) were deter-
mined based on previous small scale immunization/chal-
lenge pilot studies (data not shown).
Schistosoma mansoni challenge
Biomphalaria glabrata snails infected with the Schisto-
soma mansoni Puerto Rican strain were provided by the
NIAID Schistosomiasis Resource Center of the Biomedical
Research Institute (Rockville, MD). Cercariae, the infec-
tious stage of the parasite, were collected from the
shedding of the infected B. glabrata snails. Three weeks
after the final immunization, all of the mice were
challenged with 150 cercariae via tail exposure lasting one
hour. The mice were sacrificed seven weeks post cercarial
challenge. The adult worms were perfused from the
hepatic portal system and counted manually [26]. The
number of worms retrieved from the experimental group
was compared to the control groups in order to calculate
the percent reduction in worm burden. The livers and
intestines of the sacrificed mice were also collected. The
intestines were cut open to expose the lumen, and the
contents were cleaned out by repeated rinsing with saline.
The livers and intestines were then weighed and digested
overnight in 4 % potassium hydroxide (KOH) [26]. The
following day, the eggs present in these tissues were
counted by microscopy. The number of eggs recorded
from the experimental group was once again compared to
the control groups in order to calculate percent reduction
in egg burden. Burden reductions were calculated as
follows:
Percent worms or eggs reduction
¼ 1−Mean number of worms or eggs recovered in immunized mice






Humoral response: enzyme-linked immunosorbent assays
Blood collection via saphenous bleed was performed on
each mouse prior to each immunization as well as on
the day of the cercarial challenge. Sera were obtained by
allowing the collected blood to clot and then removing
it by centrifugation. The humoral responses elicited by
the immunizations were analyzed by enzyme-linked im-
munosorbent assay (ELISA) as described elsewhere [24].
Briefly, 96-well plates were coated with the recombinant
Sm-Cathepsin B (10 ng/well). Serial dilutions of the sera
were prepared and incubated in the antigen coated
plates. Sm-cathepsin B specific total IgG was analyzed as
well as the isotypes IgG1 and IgG2c using secondary
antibodies conjugated with horseradish peroxidase
(HRP) (total IgG-HRP from Jackson Immunoresearch
Laboratories, West Grove, PA; both IgG1-HRP and
IgG2c-HRP from Southern Biotechnologies, Birmingham,
AL). Following the addition of the substrate, 3,3′,5,5′-
tetramethylbenzidine (Millipore, Billerica, MA), the
plates were read at wavelength 450 nm. The samples
were analysed by ELISA in duplicates and data con-
firmed by a single repeat. The results are expressed
as mean endpoint titers (geometric mean and 95 %
confidence interval). Endpoint titers refer to the re-
ciprocal of the highest dilution that gives a reading
above the cut-off [27]. Based on the number of nega-
tive controls used in the ELISAs, the cut-off was
roughly equal to two standard deviations above the
mean negative values [27].
Cytokine production: multiplex ELISA
The animals were sacrificed seven weeks post cercarial
challenge. The spleens of each animal were collected
and splenocytes were isolated as described elsewhere
[24, 28]. Briefly, the spleens were crushed and the red
blood cells were lysed using ammonium-chloride potas-
sium lysing buffer. Following repeated wash and centri-
fugation steps, the cells were resuspended in complete
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media (RPMI-1640, 10 % fetal bovine serum [Wisent
Bio Products], 50 μg/ml Gentamycin, 0.05 mM 2-
Mercaptoethanol). Cell counts were determined by
trypan blue exclusion, and 106 cells/well were seeded
into 96-well plates. The cells were incubated at 37 °C
in the presence of 2 μg/ml of recombinant Sm-
cathepsin B. After 72 h, 100 μl of the supernatant
was collected. The splenocyte supernatant was used
to asses cytokine production by QUANSYS multiplex
ELISA (16-plex) (Quansys Biosciences, Logan, UT)
following the manufacturer’s recommendations.
Statistical analysis
Statistical analysis was done using the Mann–Whitney
test (nonparametric test) to compare different groups of
data. Antibody and cytokine data are presented on semi-
log plots showing geometric mean and 95 % confidence
intervals. The software GraphPad Prism 5 (La Jolla, CA)
was used. P values less than 0.05 were considered
significant.
Results
Expression of recombinant Sm-cathepsin B
The expression of the recombinant Sm-cathepsin B protein
used for the immunizations was shown by both Coomassie
staining of polyacrylamide gel (Additional file 1: Figure S1a)
and Western Blot analysis (Additional file 1: Figure S1b).
By both methods, a single and clear band representing the
protein can be observed at the expected 39 kDa region.
Lipopolysaccharide testing revealed no detectable levels of
the endotoxin.
Protective potential of Sm-cathepsin B Formulation
In order to determine the protective potential of the
Sm-cathepsin B and Montanide ISA 720 VG formula-
tion, an immunization regimen was tested using C57BL/
6 mice as described above. The average worm number
from the group that received the Sm-cathepsin B and
Montanide ISA 720 VG formulation (16.4 ± 2.5 worms)
was compared to the average from the adjuvant control
group (41.1 ± 0.8 worms). Therefore, worm burden was
reduced by 60.1 % in the mice that received the Sm-
cathepsin B/adjuvant formulation compared to the adju-
vant control mice (P = 0.0002) (Fig. 1a). Compared to
the saline control group (48.8 ± 3.5 worms), the mice
given the Sm-cathepsin B/adjuvant formulation had a
66.4 % reduction in worm burden (P < 0.0001). There
were no statistically significant difference in worm
burdens between the two control groups (P = 0.1285).
Schistosomiasis pathology is linked to the parasite eggs
becoming trapped in tissues. Hepatic and intestinal egg
burdens were determined for both the experimental and
control mouse groups. Comparisons between the
adjuvant control group (mean egg count = 11,876.0 ±
1,197.9 eggs/gram of liver) and the Sm-cathepsin B/adju-
vant formulation group (mean egg count = 4,578.5 ±
492.9 eggs/gram of liver) revealed a 61.5 % reduction
in hepatic egg burden for the mice given the vaccine
(P < 0.0001) (Fig. 1b). When comparing the experi-
mental group and the saline control (mean egg count =
14,791.6 ± 1,080.1 eggs/gram of liver) group, hepatic egg
burden is decreased by 69.1 % in the mice that received
Sm-cathepsin B/adjuvant formulation (P < 0.0001). There
also seems to be a significant decrease in hepatic egg bur-
den in the adjuvant control group compared to the saline
group (P = 0.0185).
Intestinal eggs were also enumerated from the digested
organ using microscopy. The group containing the
animals immunized with the Sm-cathepsin B/adjuvant
formulation (mean egg count = 7,292.8 ± 1,173.1 eggs/
gram of intestine) had a 56.1 % reduction in intestinal
egg burden compared to the group that received adju-
vant only (mean egg count = 16,606.6 ± 1,590.0 eggs/
gram of intestine) (P = 0.0009) (Fig. 1c). Compared to
the saline group (mean egg count = 17,800.2 ± 1,421.8
eggs/gram of intestine), the experimental group had a
59.0 % decrease in intestinal egg burden (P < 0.0001).
There were no statistically significant difference in egg
burdens between the two control groups (P = 0.4813).
All of the results elucidating the protective potential of
the Sm-cathepsin B formulation are summarized in
Additional file 2: Table S1 and Additional file 3: Table S2.
Antibody response
The serum collected throughout the immunization regi-
men was used in order to analyze and compare the anti-
body production pattern between the three groups of
mice used in this study. ELISAs were performed to de-
termine antibody titers. In both the adjuvant control and
saline control mice, there were no detectable levels of
Sm-cathepsin B specific antibodies (total IgG or IgG
subtypes IgG1 and IgG2c). In the Sm-cathepsin B/adju-
vant formulation group, Sm-cathepsin B specific total
IgG titers rose sharply after the first boost at week 3,
reaching mean endpoint titers of 40,160 at week 6, and
continued to rise until the challenge at week 9 (mean
endpoint titers = 122,880) (Fig. 2a). The sera collected
from the experimental group revealed robust production
of Sm-cathepsin B specific IgG1 that rose sharply after
the first boost at week 3. At week 6, the IgG1 mean end-
point titer was 24,960, and it continued to rise until the
challenge at week 9 (mean endpoint titer = 48,640)
(Fig. 2b). By contrast, Sm-cathepsin B specific IgG2c
production was much lower. As seen with the total IgG
and IgG1 antibody production patterns, IgG2c titers had
the most substantial increase after the first boost at week
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3. The mean endpoint titer at week 9 was found to be
1,840 (Fig. 2c).
Cytokine Production
Analysis of the cytokine panel using QUANSYS multi-
plex ELISA array revealed no significant differences in
cytokine secretion levels between the two control groups
(P > 0.05). There was an increase in Th1 cytokine
production in the group that was immunized with Sm-
cathepsin B with Montanide ISA 720 VG compared to
the control groups. There was a significant increase in
IFNγ secretion levels in the experimental group compared
to the Montanide adjuvant control group (P = 0.0021) and
the saline group (P < 0.0001) (Fig. 3a). There were also
significant increases in TNFα (P < 0.0001) and IL-12
(P = 0.0185) levels in the experimental group compared
to the adjuvant control group (Fig. 3b and c, respectively).
These increases in TNFα and IL-12 levels were also seen
when comparing the experimental group to the saline
group (P < 0.0001 and P = 0.0185, respectively). Th2
cytokine production was analyzed as well. There were
statistically significant increases in IL-4 levels between
the experimental and adjuvant groups (P = 0.0288) as
well as between the experimental and the saline
groups (P = 0.0147) (Fig. 4a). IL-5 secretion levels
were also significantly increased (P = 0.0015) in the
group immunized with the Sm-cathepsin B and
Montanide ISA 720 VG formulation compared to the ad-
juvant alone control group (Fig. 4b). This significant in-
crease was also observed when comparing the
experimental group to the saline-only group (P < 0.0001).
IL-17 levels were observed to gain insight into a possible
Th17 involvement. Secretion levels of IL-17 were sig-
nificantly increased in the experimental group com-
pared to the adjuvant control group (P = 0.0433).
However, this statistically significant increase was not
seen when comparing the experimental group to the
saline control group (P = 0.0892) (Fig. 5a). Other cyto-
kine secretion levels that were significantly increased
in the experimental group compared to the adjuvant
control group include CCL5 levels (P = 0.0002) and GM-
CSF levels (P = 0.0147) (Fig. 5b and c, respectively).
A) B)
C)
Fig. 1 Parasitological burden. The worm counts per individual mouse (P = 0.0002) a as well as the egg load per gram of liver (P < 0.0001) b and
per gram of intestine (P= 0.0009) c are represented for mice in the saline control group, the adjuvant alone control group (Montanide ISA 720VG), and
the experimental group (20 μg Sm-cathepsin B with Montanide ISA 720 VG). Worm and egg burdens were determined 7 weeks post cercarial challenge.
(ns = not significant, * P< 0.05, *** P< 0.001)
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Secretion levels of CCL5 and GM-CSF in the experimen-
tal group were significantly higher when compared to the
saline group as well (P =0.0002 and P = 0.0089,
respectively).
Discussion
Due to its essential role in parasite growth and develop-
ment and its continuous interplay with the host immune
system, our group has focused on Sm-cathepsin B as a
potential vaccine candidate. During the mid-1990s, the
WHO Special Programme for Research and Training in
Tropical Diseases (TDR/WHO) planned for the inde-
pendent testing of various Schistosoma mansoni antigens
with the hopes of uncovering an optimal vaccine candi-
date. The committee’s goal was to find an antigen that
could consistently induce 40 % protection or better [29].
Recently, our collaborators have demonstrated the in-
built adjuvant properties of Sm-cathepsin B. Immuniza-
tions with unadjuvanted Sm-cathepsin B could decrease
both worm and hepatic egg burdens in a mouse model
of schistosomiasis by 66 % and 51 %, respectively, when
compared to saline control mice [30]. However, the
intestinal egg burden was not significantly reduced
(24.7 %). The pathological importance of egg burden in
the intestines cannot be neglected. The inflammation
surrounding eggs trapped in intestinal tissues results
in the formation of severe lesions and colonic polyps
[31–33]. Furthermore, a decrease in intestinal egg burden
could reflect a consequent decrease in transmission by re-
ducing the passage of parasite eggs from the mesenteric
Fig. 2 Production of Sm-Cathepsin B specific antibodies. Sm-cathepsin B specific total IgG a, IgG1 b and IgG2c c in immunized mice: Saline control,
Montanide ISA 720 VG adjuvant control, and Sm-cathepsin B with Montanide ISA 720 VG. Serum from individual mice was analyzed by ELISA.
Geometric means and 95 % confidence intervals are shown. Endpoint titers were determined for week 0, week 3, week 6, and week 9
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veins to the intestinal lumen. The development of an anti-
schistosome vaccine needs to target all forms of parasito-
logical burden: worm, hepatic egg, and intestinal egg
burdens. The data presented in this manuscript for the
formulation of Sm-cathepsin B plus Montanide ISA 720
VG shows comparable protective results for both worm
burden; decreased by 60 % compared to adjuvant controls
and 66 % compared to saline controls. The reduction in
hepatic egg burden was greater in the animals immunized
with antigen plus adjuvant (reduction of 62 % compared
to adjuvant controls and 69 % compared to saline
controls). In this study, we showed that animals immu-
nized with Sm-cathepsin B plus Montanide ISA 720 VG
had a significant decrease in intestinal egg burden (56 %
compared to the adjuvant control animals and 59 %
compared to saline controls). The Montanide-adjuvanted
recombinant protein formulation was capable of achieving
significant reductions of all parasitological burdens
(worms, hepatic eggs, and intestinal eggs). Therefore,
using Montanide ISA 720 VG as an adjuvant with the
recombinant Sm-cathepsin B improves the protective
potential of Sm-cathepsin B.
The S. mansoni radiation attenuated (RA) cercariae
vaccine has been essential to study immune effector
mechanisms associated with protection as well as
discovering potential parasite points of vulnerability.
The RA vaccine is considered the gold standard for
reproducible induced anti-worm immunity. Exposure to
the attenuated cercariae can elicit significant protection
levels against challenges with normal cercariae. Protection
levels have been shown to range from 56 % all the way to
80 % when multiple vaccinations are performed in the
mouse model [34–37]. The protection levels attained in
this study with Sm-cathepsin B plus Montanide ISA 720
VG, 56-69 %, are beyond the 40 % threshold established
by the TDR/WHO, and are comparable to those generated
by the RA vaccine.
Several studies have demonstrated that IgG antibodies
play an important role in protection against schistosomia-
sis. The passive transfer of sera from chronically infected
or protected animals results in significantly reduced para-
site burdens in the recipient animals [38–42]. Studies
utilizing the olive baboon and rhesus macaque models
have shown that high IgG titers at the time of cercarial
challenge correlated with low worm burdens [43, 44].
Furthermore, the worms collected from the macaques,
upon perfusion, were physiologically crippled. The com-
promised structure of these worms is suggested to be a
A) B)
C)
Fig. 3 Th1 cytokine secretion levels. IFNγ (P = 0.0021) a, TNFα (P < 0.0001) b, and IL-12 (P = 0.0185) c produced 72 h after stimulating splenocytes
ex vivo with recombinant Sm-cathepsin B. Splenocytes were isolated from every C57BL/6 mice belonging to each group: Saline control (saline),
Montanide ISA 70VG control (Montanide), and Sm-cathepsin B in the presence of Montanide ISA 720 VG (SmCB +Montanide). Cytokine production
was analyzed by QUANSYS multiplex ELISA. Geometric means and 95 % confidence intervals are shown. (ns = not significant, * P < 0.05, ** P < 0.01,
*** P < 0.001)
Ricciardi et al. BMC Infectious Diseases  (2016) 16:112 Page 7 of 11
result of antibody-dependant mechanisms where IgG has
a blocking or stimulatory effect leading to parasite
starvation or exhaustion, respectively [44, 45]. In vitro
work using immune sera has also highlighted anti-
body dependant cell mediated cytotoxicity and anti-
body dependant complement mediated cytotoxicity as
potential effector mechanisms involved in protection
against schistosomiasis [41, 46]. Immunizations with
the recombinant Sm-cathepsin B in the presence of
Montanide ISA 720 VG resulted in the production of
elevated antigen-specific IgG titers in the experimental
mice (mean endpoint titers at week 9 = 122,880).
Immunization with Sm-cathepsin B alone yielded end-
point titers of approximately 3,500 [30] (data not shown)
thereby, demonstrating that the addition of the adjuvant
Montanide ISA 720 VG increases the production of Sm-
cathepsin B specific antibodies by a factor of 35. These
values demonstrate this vaccine formulation’s substantial
impact on humoral immunity. There were prominent dif-
ferences when comparing endpoint titers of different IgG
subclasses. The adjuvanted recombinant protein formula-
tion elicited a significantly stronger production of the
IgG1 subclass (mean endpoint titers at week 9 = 48,640)
over IgG2c (mean endpoint titers at week 9 = 1,840).
The IgG1 subclass is known to be representative of a
T-helper cell 2 (Th2) phenotype as its production is
stimulated by IL-4 whereas the IgG2c subclass is a
marker for a Th1 [47].
It has long been a consensus that Th1 responses play a
key role in protection against schistosomiasis. For in-
stance, peripheral blood mononuclear cells isolated from
individuals, who are considered naturally resistant to
schistosomiasis, produce high levels of interferon-
gamma (IFN-ɣ) when stimulated with schistosome
antigen [29, 48]. Moreover, immunological studies in-
volving the RA vaccine have shown that, in protected
animals, the migration of the schistosomulae is terminated
in the lungs due to the formation of inflammatory foci
consisting of monocytes and CD4+ T-cells with Th1
characteristics [37, 45, 49]. In the RA model, IL-12 was
shown to prime the Th1 response by inducing IFN-ɣ,
which then acts in an autocrine manner to amplify the re-
sponse [37, 45, 49]. The RA vaccine model has also eluci-
dated the important role of TNF-α in protection against
schistosomiasis [50]. Both Th1 cytokines IFN-ɣ and TNF-
α are secreted by cells in the inflammatory foci, and they
are both capable of activating macrophages. Other studies
with promising S. mansoni vaccine candidates have shown
an association between protection against parasite chal-
lenge and an increased IFN-ɣ production [51–53]. The
formulation of Sm-cathepsin B plus Montanide ISA 720
VG was able to significantly increase the secretion levels
of the three Th1 cytokines IFN-ɣ, TNF-α, and IL-12 com-
pared to both the saline and adjuvant controls. However,
our experimental formulation was also able to increase
the secretion levels of Th2 cytokines; the secretion levels
of IL-4 and IL-5 were significantly increased in the experi-
mental animals compared to the controls. Recent studies
have discussed the importance of inducing a Th2 response
as well to achieve protection against schistosomiasis.
Inducing such a response aims to involve eosinophils and
basophils in the response to the parasite [30, 54]. The for-
mulation of Sm-cathepsin B in the presence of Montanide
ISA 720 VG was able to stimulate both a Th1 (IFN-ɣ,
TNF-α, and IL-12) and a Th2 response (IL-4, IL-5, and
A)
B)
Fig. 4 Th2 cytokine secretion levels. IL-4 (P = 0.0288) a and IL-5
(P = 0.0015) b produced 72 h after stimulating splenocytes
ex vivo with recombinant Sm-cathepsin B. Splenocytes were isolated
from every C57BL/6 mice belonging to each group: Saline control
(saline), Montanide ISA 70VG control (Montanide), and Sm-cathepsin B
in the presence of Montanide ISA 720 VG (SmCB +Montanide).
Cytokine production was analyzed by QUANSYS multiplex ELISA.
Geometric means and 95 % confidence intervals are shown. (ns = not
significant, *P <0.05, **P < 0.01, ***P <0.001)
Ricciardi et al. BMC Infectious Diseases  (2016) 16:112 Page 8 of 11
IgG1). This resulting mixed Th1/Th2 response may ex-
plain the higher levels of protection obtained in this study
compared to our previous study using a CpG adjuvanted
Sm-cathepsin B formulation [24]. The CpG formulation
generated a more Th1-biased response. Furthermore, a
previous study showed that immunization with Sm-
cathepsin B alone leads to increased secretion of Th2-
associated cytokines such as IL-4, IL-5, and IL-13, but not
Th1-associated cytokines such as IFN-γ thus, creating a
Th2-biased response [30]. The Sm-cathepsin B +Monta-
nide ISA 720 VG also significantly increased the secretion
levels of IL-17 in the experimental animals compared to
the adjuvant control animals. This observation highlights
the potential role of Th17 responses in protection against
schistosomiasis. Increases in IL-17 levels have been corre-
lated to lower worm burdens [55]. IL-17 may contribute
to protection by mediating the recruitment and activation
of neutrophils which can impede larval migration via their
extracellular traps [54]. Furthermore, this implication of
IL-17 was not observed in our previously tested formula-
tion of Sm-cathepsin B + CpG [24] thus, demonstrating
the multi-faceted immune involvement mediated by this
Montanide adjuvanted formulation.
Levels of both GM-CSF and CCL5 were also signifi-
cantly increased in the experimental animals com-
pared to the control animals. GM-CSF is involved in
macrophage recruitment whereas CCL5 is involved in
the recruitment of T cells and granulocytes. Further-
more, CCL5 mediates proliferation and activation of
natural killer (NK) cells, which play a role in schisto-
somiasis protection in elderly populations [56]. In-
creased secretion levels of CCL5 were also observed
with our previous formulation of Sm-cathepsin B +
CpG [24]. However, elevated levels of GM-CSF were
not observed in our previous formulation thus, repre-
senting another immunological difference generated
by the formulation containing the Montanide ISA 720
VG adjuvant.
The results obtained from this study are promising
and promote further testing of the vaccine candidate
Sm-cathepsin B. In the future, the formulation can
potentially be tested in a non-human primate model of
schistosomiasis. These animals manifest a disease that is
similar to that observed in humans, and the data from
such a study may be more clinically applicable than data
from a mouse study.
C)
A) B)
Fig. 5 Th17, Chemotactic, and Growth Stimulating Cytokine levels. IL-17 (P = 0.0433) a, CCL5 (P = 0.0002) b, and GM-CSF (P = 0.0147) c produced
72 h after stimulating splenocytes ex vivo with recombinant Sm-cathepsin B. Splenocytes were isolated from every C57BL/6 mice belonging to
each group: Saline control (saline), Montanide ISA 70VG control (Montanide), and Sm-cathepsin B in the presence of Montanide ISA 720 VG
(SmCB +Montanide). Cytokine production was analyzed by QUANSYS multiplex ELISA. Geometric means and 95 % confidence intervals are
shown. (ns = not significant, *P <0.05, **P <0.01, ***P < 0.001)
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Conclusions
In summary, the data presented in this manuscript dem-
onstrated that immunizations with the formulation of
Sm-cathepsin B in the presence of Montanide ISA 720
VG generated protection levels that are comparable to
those obtained with the RA vaccine. This formulation
elicited a robust production of antigen-specific anti-
bodies and resulted in a favourable mixed Th1/Th2
response. In addition the formulation resulted in the in-
crease of other cytokines such as IL-17 and GM-CSF.
The mixed response elicited by the Sm-cathepsin B +
Montanide formulation is likely the optimal immune
scenario for the host. The essential parasite killing Th1
response was elicited (Th1) as well as the host-beneficial
injury repair Th2 response (Th2). The present study
along with our previous Sm-cathepsin B study [24]
demonstrate the importance of testing different antigen-
adjuvant combinations in order to obtain the most
protective and immunologically favourable formulation.
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